Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||EED226 + Pomalidomide|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|EED226||EED226 is a small molecule inhibitor of PRC2 via direct binding to the H3K27me3 pocket of EED, which leads to altered PRC2 targeted gene expression and thus, may result in inhibition of cell proliferation, blockade of tumor growth, and tumor regression (PMID: 28135235).|
|Pomalidomide||Pomalyst||CC-4047||Pomalyst (pomalidomide) is a thalidomide derivative that inhibits angiogenesis and modulates immune response, potentially lead to antitumor activity (PMID: 30069630). Pomalyst (pomalidomide) is FDA approved for use in patients with Kaposi's sarcoma who failed HAART or are HIV-negative, and in combination with dexamethasone in patients with multiple myeloma who had 2 or more prior therapies (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|